Emerging data suggest that resident cells and locally produced mediators interact with nerves in the joint to promote pain in rheumatoid arthritis. This Review discusses the potential neuro–immune–stromal interactions promoting joint pain and highlights the need for an interdisciplinary approach to therapeutic development.

The first guidelines for the screening, monitoring and treatment of interstitial lung disease (ILD) in patients with systemic autoimmune rheumatic diseases (SARDs) are now available after a major multidisciplinary effort by the ACR and the American College of Chest Physicians. These guidelines demonstrate that multidisciplinary collaborations can improve SARD-ILD management.

CAR T cell therapy shows promise for achieving long-term drug-free remission in various autoimmune diseases. This Review discusses the ongoing challenges and unanswered questions of CAR T cell therapy in autoimmune diseases, including pre-procedural, procedural and post-procedural considerations.

Consistent with findings from clinical trials, in a retrospective cohort study, Janus kinase inhibitors improved pain associated with rheumatoid arthritis as well as or better than biologic DMARDs in clinical practice.

Neoself-antigens presented by MHC-II molecules in the absence of invariant chain drive clonal expansion of autoreactive T cells in SLE.

The bispecific T cell engager antibody teclistamab has now been used to successfully treat five patients with treatment-resistant autoimmune rheumatic diseases.

A study has compared the safety and efficacy of three different immunomodulatory drugs combined with glucocorticoids for the treatment of Behçet uveitis.

Findings show a role for the PU.1–IL-9 axis in T_H9 cells in the pathogenesis of RA.

Researchers have identified a mechanistic link between SARS-CoV-2 infection and multisystem inflammatory syndrome in children, providing evidence for the involvement of molecular mimicry.